|
Real-time Estimate
Cboe BZX
20:29:18 19/11/2026 GMT
|
5-day change | 1st Jan Change | ||
| 395.80 USD | -0.57% |
|
-7.02% | -32.10% |
Company Valuation: Madrigal Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,449 | 5,179 | 4,568 | 6,730 | 13,226 | 9,247 | - | - |
| Change | - | 257.45% | -11.79% | 47.33% | 96.52% | -30.08% | - | - |
| Enterprise Value (EV) 1 | 1,179 | 4,869 | 4,051 | 5,922 | 12,584 | 8,612 | 8,291 | 7,214 |
| Change | - | 313.04% | -16.81% | 46.21% | 112.48% | -31.56% | -3.74% | -12.98% |
| P/E | -5.79x | -16.8x | -11.6x | -14.1x | -45.3x | -231x | 57.9x | 19.1x |
| PBR | 7.15x | 26.6x | 11.3x | 9x | 22.1x | 16.4x | 11.5x | 5.58x |
| PEG | - | -0.9x | -0.7x | -1.48x | 1.1x | 2.7x | -0x | 0x |
| Capitalization / Revenue | - | - | - | 37.4x | 13.8x | 5.84x | 4.23x | 3.2x |
| EV / Revenue | - | - | - | 32.9x | 13.1x | 5.44x | 3.79x | 2.5x |
| EV / EBITDA | -4.87x | -16.6x | -10.7x | -11.9x | -42.1x | -165x | 66.4x | 12.3x |
| EV / EBIT | -4.86x | -16.6x | -10.6x | -11.9x | -41.9x | -186x | 39.6x | 10.5x |
| EV / FCF | -4.87x | -16.6x | -12.4x | -13x | -66.2x | -365x | 17.9x | 8.03x |
| FCF Yield | -20.6% | -6.01% | -8.04% | -7.72% | -1.51% | -0.27% | 5.6% | 12.5% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -14.63 | -17.23 | -19.99 | -21.9 | -12.85 | -1.72 | 6.877 | 20.81 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | 180.1 | 958.4 | 1,584 | 2,185 | 2,888 |
| EBITDA 1 | -242.1 | -293.1 | -380 | -496.8 | -298.6 | -52.17 | 124.8 | 584.4 |
| EBIT 1 | -242.5 | -293.6 | -380.5 | -497.9 | -300.1 | -46.39 | 209.6 | 684.8 |
| Net income 1 | -241.8 | -295.4 | -373.6 | -465.9 | -288.3 | -49.57 | 215.8 | 660.3 |
| Net Debt 1 | -269.9 | -309.5 | -517.5 | -807.7 | -642 | -635 | -956.7 | -2,033 |
| Reference price 2 | 84.74 | 290.25 | 231.38 | 308.57 | 582.34 | 398.08 | 398.08 | 398.08 |
| Nbr of stocks (in thousands) | 17,097 | 17,842 | 19,743 | 21,810 | 22,711 | 23,230 | - | - |
| Announcement Date | 24/02/22 | 23/02/23 | 28/02/24 | 26/02/25 | 19/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
| -231.48x | 5.44x | -165.07x | -.--% | 9.25B | ||
| 17.09x | 6.54x | 12.53x | 1.75% | 65.45B | ||
| 31.87x | 8.51x | 28.12x | 0.07% | 58.93B | ||
| 38.62x | 6.88x | 20.56x | 0.84% | 55.21B | ||
| 43.31x | 6.04x | 28.76x | -.--% | 46.1B | ||
| 33.65x | 3.22x | 13.91x | -.--% | 42.49B | ||
| 35.05x | 8.68x | 22.64x | 0.37% | 35.56B | ||
| -18.94x | 54.62x | -20.7x | -.--% | 34.57B | ||
| 41.52x | 8.01x | 26.86x | -.--% | 32.46B | ||
| -74.21x | 13.84x | -79.52x | -.--% | 26.28B | ||
| Average | -8.35x | 12.18x | -11.19x | 0.3% | 41B | |
| Weighted average by Cap. | 15.76x | 11.31x | 7.07x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- MDGL Stock
- Valuation Madrigal Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
















